Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- March 2014
- Editorial
Limits on Use of Health Economic Assessments for Rare Diseases
By: Hanna I. Hyry, Ariel Dora Stern, Jonathan CP Roos and Timothy M. Cox
Funding of expensive treatments for rare ('orphan') diseases is contentious. These agents fare poorly on 'efficiency' or health economic measures, such as the QALY, because of high cost and frequently poor gains in quality of life and survival. We show that... View Details
Hyry, Hanna I., Ariel Dora Stern, Jonathan CP Roos, and Timothy M. Cox. "Limits on Use of Health Economic Assessments for Rare Diseases." hcu016. QJM: An International Journal of Medicine 107, no. 3 (March 2014): 241–245.
- April 2014 (Revised July 2015)
- Case
Sanofi Pasteur: The Dengue Vaccine Dilemma
By: V. Kasturi Rangan, David E. Bloom, Vincent Dessain and Emilie Billaud
In 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a... View Details
Keywords: Health Testing and Trials; Product Launch; Market Entry and Exit; Emerging Markets; Pharmaceutical Industry; France
Rangan, V. Kasturi, David E. Bloom, Vincent Dessain, and Emilie Billaud. "Sanofi Pasteur: The Dengue Vaccine Dilemma." Harvard Business School Case 514-074, April 2014. (Revised July 2015.)
- October 1994
- Case
Nippon Kayaku
By: Robin Cooper, Takeo Yoshikawa and Robert S. Kaplan
Cooper, Robin, Takeo Yoshikawa, and Robert S. Kaplan. "Nippon Kayaku." Harvard Business School Case 195-068, October 1994.
- 2013
- Working Paper
Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case
By: Robert Lagerstrom, Carliss Baldwin, Alan MacCormack and David Dreyfus
We test a method that was designed and used previously to reveal the hidden internal architectural structure of software systems. The focus of this paper is to test if it can also uncover new facts about the components and their relationships in an enterprise... View Details
Lagerstrom, Robert, Carliss Baldwin, Alan MacCormack, and David Dreyfus. "Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case." Harvard Business School Working Paper, No. 13-105, June 2013.
- September 2012 (Revised November 2014)
- Case
Cialis Lifecycle Management: Lilly's BPH Dilemma
By: Elie Ofek and Natalie Kindred
How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new... View Details
Keywords: Product Positioning; Attitudes; Brands and Branding; Pharmaceutical Industry; United States
Ofek, Elie, and Natalie Kindred. "Cialis Lifecycle Management: Lilly's BPH Dilemma." Harvard Business School Case 513-005, September 2012. (Revised November 2014.)
- May 2011 (Revised July 2012)
- Exercise
Remicade/Simponi: Confidential Instructions for Merck
By: Guhan Subramanian and Rhea Ghosh
This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details
Keywords: Price; Rights; Agreements and Arrangements; Negotiation Deal; Problems and Challenges; Risk and Uncertainty; Pharmaceutical Industry
Subramanian, Guhan, and Rhea Ghosh. "Remicade/Simponi: Confidential Instructions for Merck." Harvard Business School Exercise 911-044, May 2011. (Revised July 2012.)
- December 2010
- Teaching Note
Organization and Strategy at Millennium (TN) (A) & (B)
By: Julie M. Wulf
Teaching Note for 710-415 and 710-418. View Details
- April 2009
- Teaching Note
Amylin Pharmaceuticals: Diabetes and Beyond (TN)
By: Richard G. Hamermesh and Rachel Gordon
Teaching Note for [809011]. View Details
- April 2009
- Supplement
Merck: Managing Vioxx (G)
By: Robert L. Simons and Natalie Kindred
Keywords: Decision Choices and Conditions; Leadership; Customer Focus and Relationships; Pharmaceutical Industry
Simons, Robert L., and Natalie Kindred. "Merck: Managing Vioxx (G)." Harvard Business School Supplement 109-086, April 2009.
- April 2009 (Revised April 2010)
- Supplement
Merck: Managing Vioxx (F)
By: Robert L. Simons and Natalie Kindred
Simons, Robert L., and Natalie Kindred. "Merck: Managing Vioxx (F)." Harvard Business School Supplement 109-085, April 2009. (Revised April 2010.)
- April 2009
- Supplement
Merck: Managing Vioxx (D)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (D)." Harvard Business School Supplement 109-083, April 2009.
- April 2009
- Supplement
Merck: Managing Vioxx (C)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (C)." Harvard Business School Supplement 109-082, April 2009.
- April 2009 (Revised April 2010)
- Supplement
Merck: Managing Vioxx (B)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (B)." Harvard Business School Supplement 109-081, April 2009. (Revised April 2010.)
- 2008
- Case
Eli Lilly: Recreating Drug Discovery for the 21st Century
By: Rebecca Henderson and C. Reavis
- May 2006
- Teaching Note
WuXi PharmaTech (TN)
By: Richard G. Hamermesh and Erin Seefeld
Keywords: Pharmaceutical Industry
- March 2006 (Revised February 2009)
- Teaching Note
Molecular Insight Pharmaceuticals, Inc. (TN)
By: Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-067). View Details
Keywords: Pharmaceutical Industry
- February 2005 (Revised March 2005)
- Teaching Note
Product Team Cialis: Getting Ready to Market (TN)
By: Elie Ofek
Teaching Note to (9-505-038). View Details
- February 2005 (Revised April 2006)
- Case
Rx Depot: Importing Drugs from Canada
By: Debora L. Spar
In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot... View Details
Keywords: Courts and Trials; Entrepreneurship; Intellectual Property; Laws and Statutes; Pharmaceutical Industry; Canada; United States
Spar, Debora L., and Adam Day. "Rx Depot: Importing Drugs from Canada." Harvard Business School Case 705-010, February 2005. (Revised April 2006.)
- 2003
- Chapter
La tragédie de la thalidomide: affaires judiciaries et résponses législatives, 1959-1971
By: Arthur A. Daemmrich
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)